title: EFNS guideline on diagnosis and management of post-polio syndrome. Report of an EFNS task force.
abstract: Post-polio syndrome (PPS) is characterized by new or increased muscular weakness, atrophy, muscle pain and fatigue several years after acute polio. The aim of the article is to prepare diagnostic criteria for PPS, and to evaluate the existing evidence for therapeutic interventions. The Medline, EMBASE and ISI databases were searched. Consensus in the group was reached after discussion by e-mail. We recommend Halstead's definition of PPS from 1991 as diagnostic criteria. Supervised, aerobic muscular training, both isokinetic and isometric, is a safe and effective way to prevent further decline for patients with moderate weakness (Level B). Muscular training can also improve muscular fatigue, muscle weakness and pain. Training in a warm climate and non-swimming water exercises are particularly useful (Level B). Respiratory muscle training can improve pulmonary function. Recognition of respiratory impairment and early introduction of non-invasive ventilatory aids prevent or delay further respiratory decline and the need for invasive respiratory aid (Level C). Group training, regular follow-up and patient education are useful for the patients' mental status and well-being. Weight loss, adjustment and introduction of properly fitted assistive devices should be considered (good practice points). A small number of controlled studies of potential-specific treatments for PPS have been completed, but no definitive therapeutic effect has been reported for the agents evaluated (pyridostigmine, corticosteroids, amantadine). Future randomized trials should particularly address the treatment of pain, which is commonly reported by PPS patients. There is also a need for studies evaluating the long-term effects of muscular training.
authors.affiliation: Department of Neurology, Haukeland University Hospital, University of Bergen, Bergen, Norway. elfa@sir.no European Federation of Neurological Society
authors.forename: E
authors.initials: E
authors.lastname: Farbu
authors.forename: N E
authors.initials: NE
authors.lastname: Gilhus
authors.forename: M P
authors.initials: MP
authors.lastname: Barnes
authors.forename: K
authors.initials: K
authors.lastname: Borg
authors.forename: M
authors.initials: M
authors.lastname: de Visser
authors.forename: A
authors.initials: A
authors.lastname: Driessen
authors.forename: R
authors.initials: R
authors.lastname: Howard
authors.forename: F
authors.initials: F
authors.lastname: Nollet
authors.forename: J
authors.initials: J
authors.lastname: Opara
authors.forename: E
authors.initials: E
authors.lastname: Stalberg
mesh_terms: D026683:Advisory Committees; D000547:Amantadine / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use; D005060:Europe; D005081:Exercise Therapy / Q000379:methods; D006801:Humans; D016239:MEDLINE / Q000706:statistics & numerical data; D008279:Magnetic Resonance Imaging; D009462:Neurology; D009482:Neurophysiology / Q000379:methods; D010808:Physical Examination; D016262:Postpoliomyelitis Syndrome / Q000175:diagnosis* / Q000503:physiopathology / Q000628:therapy*; D017410:Practice Guidelines as Topic; D012955:Societies, Medical; D013256:Steroids / Q000627:therapeutic use
chemical_list: D000998:Antiviral Agents; D002800:Cholinesterase Inhibitors; D013256:Steroids; D000547:Amantadine